Rapport Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPP research report →
Range $52 – $80
Price Chart
About the company
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity).
- CEO
- Abraham N. Ceesay
- IPO
- 2024
- Employees
- 84
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on RAPP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.49B
- P/E
- -10.25
- PEG
- 0.47
- P/S
- 74.49
- P/B
- 3.50
- EV/EBITDA
- -9.70
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -767.58%
- Net Margin
- -685.80%
- ROE
- -29.02%
- ROIC
- -35.45%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-125,099,000
- Net Income
- $-111,483,000-42.4%
- EPS
- $-2.86+24.3%
- OCF Growth
- -34.9%
- FCF Growth
- -31.0%
- 52W High
- $52.93
- 52W Low
- $23.75
- 50D MA
- $43.33
- 200D MA
- $35.79
- Beta
- 1.03
- RSI (14)
- 23
- Avg Volume
- 379.80K
No earnings-call transcripts are available for RAPP yet.
- Free Float
- 47.8%
- Shares Outstanding
- 47.83M
- Float Shares
- 22.88M
of shares held by institutions
166 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 7.17M | ▲ 3.96K |
| Trv Gp V, LLC | 6.28M | ▼ 854.71K |
| Arch Venture Management, LLC | 3.73M | 0 |
| Capital International Investors | 2.92M | ▼ 176.01K |
| Goldman Sachs Group Inc | 2.91M | ▼ 31.80K |
| Blackrock, Inc. | 2.70M | ▲ 193.83K |
| Cormorant Asset Management, LP | 2.66M | ▼ 300.00K |
| Sofinnova Investments, Inc. | 1.90M | 0 |
| Vanguard Group Inc | 1.82M | ▲ 191.22K |
| Johnson & Johnson | 1.78M | 0 |
| Polar Capital Holdings PLC | 1.61M | ▼ 33.95K |
| Baker Bros. Advisors LP | 1.55M | 0 |
Held by 202 ETFs
Biggest fund positions in RAPP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Gault Cheryl | sell | 7,925 |
| Sep 30, 26 | Gault Cheryl | sell | 2,075 |
| Sep 23, 26 | Ceesay Abraham | sell | 1,952 |
| Sep 23, 26 | Ceesay Abraham | sell | 215 |
| Sep 23, 26 | Ceesay Abraham | sell | 43 |
| Sep 8, 26 | Ceesay Abraham | sell | 7,141 |
| Sep 8, 26 | Ceesay Abraham | sell | 1,069 |
| Aug 25, 26 | Ceesay Abraham | sell | 18,921 |
| Aug 24, 26 | Yeleswaram Krishnaswamy | sell | 13,160 |
| Aug 25, 26 | Yeleswaram Krishnaswamy | sell | 20,799 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RAPP coverage
Recent articles, reports, and earnings notes.
No research on RAPP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAPP report →Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade
seekingalpha.com · Sep 24
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript
seekingalpha.com · Sep 22
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
zacks.com · Sep 22
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
benzinga.com · Sep 16
Legal & General Group Plc Acquires Shares of 22,555 Rapport Therapeutics, Inc. $RAPP
defenseworld.net · Sep 8
Rapport Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 2
Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP
defenseworld.net · Aug 30
Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP
defenseworld.net · Aug 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.